Global pharmaceutical firm Novo Nordisk on Feb. 24 announced that as of Jan. 1, 2027, it will lower the list price, or wholesale acquisition cost, for its popular weight-loss drugs Ozempic and Wegovy by up to 50 percent.
This will include Wegovy (semaglutide) 2.4 injections and 25 mg tablets, Ozempic (semaglutide) 0.5 mg, 1 mg, and 2 mg injections, and Rybelsus (semaglutide) 7 mg or 14 mg tablets to $675—equating to a reduction of nearly 50 percent for Wegovy and 35 percent of Ozempic from the current list prices.
